Our experimental design was based on a straightforward immunohistochemical study of LC3 and FtMt using antibodies that are well-characterized and validated for use in human tissues, including PSP patients’ tissues [6,23]. The gene discussed is MAP1LC3A; the disease is supranuclear palsy, progressive, 1.